Abstract 676TiP
Background
This is the first clinical trial of an in vivo chimeric antigen receptor (CAR) therapy. The in vivo approach, with repeat dosing and no conditioning, has the potential to overcome many of the challenges of ex vivo CAR therapies. MT-302, an mRNA-lipid nanoparticle (LNP) formulation for intravenous delivery, allows for dose and schedule optimization. The mRNA encodes for a receptor consisting of a TROP2-targeted scFv, as well as the transmembrane domain and cytoplasmic tail of CD89. Upon MT-302 dosing the LNP is taken up by numerous cell types, but a functional CAR can only be expressed on the surface of cells that also express the Fc receptor common gamma chain, predominately myeloid cells. In vivo delivered MT-302 resulted in TROP2 CAR expression and anti-tumor efficacy in an HCC-1954 breast cancer xenograft model (Argueta, AACR 2024, #1321). In a syngeneic model, in vivo delivered surrogate CD89-based CAR treatment inhibited tumor growth with demonstrated intra-tumoral accumulation of activated CD8+ T cells and reduced tumor associated Tregs (Prod'homme, AACR 2023, LB027). Thus, this first-in-class in vivo CAR-M (myeloid) therapy will be tested to treat TROP2 expressing cancers with the goal of infiltrating the tumor microenvironment and initiating a broad anti-tumor immune response.
Trial design
MYE Symphony is a multicenter first-in-human study of MT-302 in participants with advanced epithelial cancers enriched for high TROP2 expression. MT-302 is given every 14 days for 3 doses followed by administration once every 28 days. The dose escalation employs a Bayesian Optimal Interval design with backfill for further dose evaluation. Primary endpoints are to assess safety and define the MTD and RP2D. Secondary endpoints include defining the PK and rates of ICANs and CRS. Exploratory endpoints include efficacy measures (e.g. ORR and DOR) and treatment induced immunologic impact (e.g. peripheral CAR expression, cytokine release, and T cell receptor clonality, as well as changes in the tumor immune environment and TROP2 expression). The first three dose level cohorts have been enrolled. NCT05969041.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Myeloid Therapeutics.
Funding
Myeloid Therapeutics.
Disclosure
M. Churchill, M. Barnett, M. Cioffi: Financial Interests, Personal and Institutional, Full or part-time Employment: Myeloid Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
621P - Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Presenter: Yoshitaka Honma
Session: Poster session 01
622P - Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
Presenter: Zhengbo Song
Session: Poster session 01
624P - Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Presenter: Rafal Dziadziuszko
Session: Poster session 01
625P - Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications
Presenter: Marwan Fakih
Session: Poster session 01
626P - Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster session 01
627P - Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Presenter: Alexander Drilon
Session: Poster session 01
628P - Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
Presenter: David Hong
Session: Poster session 01
629P - Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Presenter: Siqing Fu
Session: Poster session 01